Merck's Catalysts Spark Bull-Bear Debate Among Analysts

Merck's near-term catalysts have created a debate among analysts regarding the company's future prospects. RBC Capital Markets has weighed in on this discussion, presenting both bullish and bearish views. According to the firm, Merck's pipeline of products, including its oncology franchise, is expected to drive growth in the coming quarters.

The company's key catalysts for near-term growth include the potential approval of its cancer treatment, pembrolizumab, by regulatory bodies such as the FDA. Additionally, RBC Capital Markets notes that Merck's pipeline of new products will continue to expand, providing a steady stream of revenue in the future.

However, some analysts have raised concerns about the company's ability to sustain its growth momentum. They argue that Merck's dependence on its existing product portfolio and the potential risks associated with its pipeline make it vulnerable to market fluctuations.